

Xerostomia: Post Radiation Management Strategies

Ayesha Tariq*, Muhammad Jamshaid, Imtiaz Majeed
University of central Punjab, Lahore, Punjab, Pakistan
*Email: ayeshatariq592@gmail.com

Subject: Pharmacology

Abstract

Xerostomia is clinically denoted by feeling of dryness in the mouth due to decreased production of saliva. Prevalence of this condition is about 20% in the general population with highest rate of incidence in females and elderly people. Xerostomia (feeling of dryness) can impair the patient's ability of speaking, swallowing and chewing, but the extent of dysfunction is dependent on the dose of radiation and the size of irradiated tissues. Average radiation dose of 10 to 15 Grays is associated with minimum dysfunction of salivary glands. But when the radiation dose is greater than 40 Gray, then maximal dysfunction (approx 75%) is observed in the salivary glands which are radiosensitive in nature. When radiotherapy induced in xerostomia, patients they are at highest risk of developing oral infections like gingivitis, periodontitis, viral and as well as fungal infections. Xerostomia can be managed by various means such as intensity modified radiation therapy (IMRT), transplantation of salivary glands, sialogogues (saliva stimulants), oral hygiene and by different salivary substitutes or artificial saliva. This brief study give explanation about different management approaches for radiotherapy induced xerostomia.

Keywords: *Xerostomia, Xerostomia management, salivary substitutes, artificial saliva*

1. Introduction

In head and neck treatment, radiotherapy is generally used as definitive treatment either alone or concomitantly with surgery and chemotherapy. One of the most alarming side effects associated with radiation therapy is mouth dryness[1, 2]. The term dry mouth was first time described by bartley as medical symptom in 1868. According to him, clinical manifestation of this condition was based on dryness of buccal mucosa and abolition of salivary ducts[3]. After 21 years, In 1889, Hutchinson was the person, who gave the name 'xerostomia' to this condition[4]. Xerostomia is usually defined as subjective feeling of dryness in the mouth [5]due to the reason of having viscous, decreased or lack of salivary secretions[[6, 7]. According to the National Institute of Dental and Craniofacial Research-National Institutes of Health (NIDCR), it is a medical condition in which patient is unable to moist his mouth normally due to absence of sufficient saliva[8]. Parotid, submandibular, sublingual and some minor salivary glands(lingual, labial, buccal, palatine, glossopalatine) are mainly

involved in saliva production which can be unstimulated(resting) and stimulated[9, 10]. Along with other glands, about 60-70% of stimulated saliva is produced mainly by parotid gland(with flow rate 0.2-0.7ml/min) but for the most part of submandibular and sublingual glands and minor salivary glands are involved in unstimulated saliva production(approx 65% with flow rate of >0.1ml/min).While rest of the unstimulated saliva is contributed by parotid gland(20%) and the sublingual gland(7-8%)[11, 12].In healthy person, normal saliva flow is about 500ml-1.5L per day[9, 13]but in xerostomic condition, salivary flow rate is less than 0.1ml/min[14]. Xerostomia may be expected from the hypo functioning of salivary glands in which composition and quantity of saliva is changed[15]. Acinar atrophy and persistent swelling of salivary glands are hallmarks of radiation associated injury(resultant effects of radiation-induced apoptosis and necrosis)[1] that leads to dysfunction of salivary secretions[16]. Xerostomia has a negative effect on

patient's health status [17, 18] because dryness enhances the vulnerability to infection and as a result patient's power of speaking, chewing and swelling will be compromised[19]. Radiation dose of up to 70Gy is usually required in combination with chemotherapy to treat the oral cancer but above 40Gy radiation dose is enough to produce damaging impact on salivary flow rate (amount of saliva production)[20, 21]. For the treatment of all types of HNC, radiation in fractionated doses (2.0Gy/d*5d) are administered up to the total dose of 50-70Gy over 5-7 weeks [9] and severe dysfunction of salivary glands occur when major salivary glands are involved in irradiation field[16]. Salivary glands specially parotid glands are extremely radiosensitive[22]. Single radiation dose of 20-40Gy have potential to stop the salivary flow permanently[21]. It is evident from previous studies that each gland is responsible

for approximately 4%–5% reduction in the parotid gland output[23, 24]. The total output reduction is highly influenced by radiation field (table 1) [21]. It is documented in Ohn and colleagues study that RT decreases the saliva flow rate and increasing the chance of oral complications. After evaluating 18 patients, they found that an association is present between alteration of salivary function and frequency of oral complications[25]. Xerostomic condition can lead to further complications such as persistent dry mouth, mucosal changes, plaque accumulation, injuries of oral mucosa, halitosis[26], nocturnal oral discomfort, Oropharyngeal burning, Thirst, denture stomatitis[27], Candidiasis[28], oral mucositis, dysphagia[29, 30], enamel erosion, root caries, periodontal diseases[31, 32], Changes in oral microbial flora, decreased dietary intake and change in taste alteration[33, 34]

Table no 1: Radiation field Vs reduction of salivary flow

Radiation field	Reduction % of salivary flow
Bilateral radiotherapy	Upto 80%
Unilateral RT	50-60%
Mantle therapy	30-40%

Table no 2: Delayed complications due to radiotherapy

Complications	Radiation dose	References
Xerostomia	>50Gy	[35]
Osteoradionecrosis (ORN)	≥66Gy	[36]
Radiation fibrosis (RF)	>40Gy/>60Gy	[37]
Trismus	>55Gy	[38]
Stricture and Dysphagia	≥ 50 Gy	[39]
Moderate to severe carotid disease	≥ 50 Gy	[40]
Pituitary-Hypothalamic Dysfunction	30-50Gy	[41]
Thyroid dysfunction	30-70Gy	[42]
Radiation-induced cataracts	>8-10Gy	[43]
Dry eyes	>57Gy	[44]
Non proliferative retinopathy (NPR)	45-55Gy or >55Gy	[45]
Ototoxicity	>50Gy	[46]
Temporal lobe necrosis (TLN)	BED>80Gy	[47]
Brachial plexopathy	43.5 to 60 Gy	[48]

2. Prevalence

In one study, prevalence between 10 and 50% is reported for xerostomia. In general population, its prevalence is about 20% with increased incidence in females (up to 30%) and in elderly (up to 50%)[15, 49, 50].

3. Measurement and Grading of the Xerostomia

It is very necessary to accurately measure the severity of xerostomia. At present, the most important xerostomic measurement parameters are (1) functional imaging of gland activity e.g Plain-Film Radiography[51], ultrasonography[52, 53], Computed Tomography(CT) , magnetic resonance imaging(MRI)[54], Scintigraphy[[55, 56], Conventional sialography[57], MR Sialography[58, 59] (2) Salivary output measurements either directly by collection of whole-mouth saliva (stimulated /unstimulated)[60] or indirectly by salivary gland Scintigraphy[61](3) observer-assessed toxicity grading e.g Common Terminology Criteria for Adverse Events (CTCAE) and Visual Analog Scale (VAS)[62], and (4) patient-reported assessment of the variety of xerostomia-related symptoms e. g xerostomia questionnaires[63, 64].

4. Management of xerostomia

In order to effectively manage the xerostomia (both acute and chronic cases), frequent evaluation and support is essential to the patient’s welfare by embracing an individual treatment schedule (contain all contributing factors of whole mouth care) [21]. Palliative measures (local and systemic) included in the main focal points of existing managing strategies of xerostomia. Management protocol of xerostomia basically relies on residual secretory propensity of the salivary glands [38]. Salivary output is affected by many predisposing factors such as dose of radiation, degree of dryness and use of concurrent medications[67]. Additionally, various assessment methods of xerostomia have great influence on measuring parameters of salivary output, physicians’ evaluation strategy to score xerostomia, and individual ’s own assessment scoring[63, 68]. Significantly, clinicians’ grading assessments often different from patient assessments [65]. Eventually, the main objective of management intervention should be relief of xerostomic associated symptoms that have a negative impact on individual’s quality of life. Therefore, the most efficient intervention for salivary dysfunction is preventive measures of xerostomia[38].


Table no 3: Common Terminology Criteria for Adverse Events (CTCAE) is used to clinically evaluate the severity of xerostomia [65].

Grades	Description	Salivary flow (unstimulated) (ml/min)
One (Mild)	Symptomatic (dry / thick saliva) without significant dietary alteration	>0.2
Two (Moderate)	Symptomatic and significant oral intake alteration (e.g., copious water, other lubricants, diet limited to purees and/or soft, moist foods)	0.1 to 0.2
Three (Severe)	Symptoms leading to inability to adequately aliment orally; IV fluids, tube feedings, or TPN indicated.	<0.1

Table no 4: Grading of Xerostomia by RTOG system[66]

Grades	Acute	Chronic
	(within 90 days from the start of RT)	(Beyond 90 from the start of RT)
One	Slightly thickened saliva, additional fluids may be required	Slight dryness of the mouth; good response to stimulation
Two	Thick, sticky saliva. Alteration in diet is required	Moderate dryness of the mouth, poor response to stimulation
Three	Inadequate oral nutrition related to salivary gland changes	Complete dryness of the mouth; no response to stimulation
Four	Acute salivary gland necrosis	Fibrosis

Figure no 1: Advanced management strategies for xerostomia[69]



5. Stringent dental and oral hygiene

Oral preventive measure is one of the leading approaches to diminish the radiotherapy induced complications before, during and after the treatment of HNC. Before starting radiation therapy, it is recommended that patients should frequently undergo complete dental checkup that will help to tackle all the possible causes of oral infections and preexistent oral diseases[70, 71] [72]. During and after radiotherapy, rigorous oral care is one of the most important element of xerostomia management protocol that decreases the chances of patient's susceptibility to dental caries, plaque and gingivitis[73].

5.1 Salivary glands-sparing radiation techniques

From previous studies, it has been established that risk of xerostomia can be reduced significantly with sparing of at least one of the major salivary glands by keeping mean radiation dose of $\leq 26\text{Gy}$ [74, 75]. Portaluri M et al. has recognized in his dosimetric and clinical evaluation study that patient experienced mild or no subjective feeling of xerostomia by contralateral exposure to parotid gland with mean radiation dose of $<30\text{Gy}$ [12]. In 2006, Meirovitz and his colleague found that whole regaining of salivary production can be possible if 33% volume of parotid gland to be exposed contralaterally with mean dose of $>40\text{Gy}$ [65]. In one of the recent study, it has been proved that severe xerostomia can be avoided by keeping either mean radiation dose of 20Gy to one of the parotid gland or 25Gy to both parotid glands [76].

Currently, the most important salivary glands sparing radiotherapy techniques are 3-dimensional conformal RT, intensity-modulated RT (IMRT) and proton RT[76, 77]. These techniques possess improved cytotoxic efficiency by allowing increased doses to cancerous tissues while minimum harm to normal tissues [23]. These functions are achieved by intended delivery and thereby having better control on localized tumor hence reducing the RT associated morbidity and enhancing the xerostomia related quality of life[23, 76].

5.2 Restoration strategies to improve residual salivary functions

5.2.1 Sialogogue

The word sialogogue has been derived from the two Greek words sialan (saliva); and agogos (leading) [82]. A sialogogue is characterized by anything (either medicinal agent or a substance) that have potential to stimulate the saliva secretion by promoting the salivary glands function which ultimately leads to enhance the flow of saliva [82, 83]. Saliva stimulant, Sialogogue, Ptyalagogue or Ptyalagogue are other alternative terms used in place of sialogogue [83]. Stimulating effect of sialogogues can be achieved either by Mechanical and gustatory stimulation or by use of medication (table 5)[84]. Salivary secretion can also be induced by electrical stimulation e.g. Salitron that is Intra-oral electronic stimulator of saliva, and by chemical stimulants such as Mouth-Kote (having Mucopolysaccharide Sol with citric acid) and Optimoist (containing citric acid)[85].

Table no 5: Approaches utilized in oral health optimization

Approaches utilized in oral health optimization	References
<ul style="list-style-type: none"> • Meticulous oral hygiene • Frequent assessment of dental and mucosal health status • Suitable interventions to improve oral complications 	[23]
Rigorous oral care include	
<ul style="list-style-type: none"> • Oral hygiene (plaque control; use of Chlorhexidine, fluoride mouthwash, or fluoride gel daily, High fluoride toothpaste; Complete education of Oral hygiene) • Dentures • Antifungal (Nystatin pastilles, Amphotericin B lozenges, Miconazole gel) 	[21]

Table no 6: Benefits against two dimensional radiotherapy

Advanced techniques	Benefits against two dimensional radiotherapy	References
IMRT (intensity modulated radiotherapy)	Precise release of radiation dosage. Accurate distribution of radiation dose to the tumor tissue. Provide better opportunity to spare major salivary glands. Impart significant protection to healthy tissues against cumulated radiation dose. Preserve the sufficient salivary flow rate. Marked diminution of patient- and observer-rated xerostomia.	[78, 79]
Proton radiotherapy	Allowing greater radiation dose distribution in contrast to existing X-ray (photon) RT. Sparing of normal tissues by delivering of minimum dose to them. Considerable declining of radiotherapy induced acute and delayed side effects.	[80, 81]

Table no 7: Sialogogue

Sialogogues				
Mechanical and gustatory stimulants[86]		Pharmacological stimulants		
Examples	Description	Drugs	Pharmacological class	Dose
Chewing gum (Biotène and Oral Balance products) Other chewgums e.g V6 (Stimorol) and Freedent (Wrigley)	Improve mouth wetting, reduce oral infection by stimulating watery(thin)saliva	Pilocarpine Hc [2, 87]	Cholinergic agonist	Initial recommended dose is 5mg, 3or 4 times /day (usual dose range 15-30mg/day) [88]
Sucking ointment	Helps to stimulate saliva having foamy consistency, mild taste and longer effect.	Cevimeline [89]	Cholinergic agonist having high affinity for M3 receptor	30mg 3 times per day[90]
Taste Menthol Sweet Acid(citric acid)	Aid in producing the mucous saliva Marks the bitter taste of vitamin acid.	Bethanechol	cholinergic–muscarinic agonist	25mg 3 times in a day[250].
		Paramethoxyphenylpropene [[91]		25mg , 3 times daily
Vitamin C tablets.	Lessen the viscosity of saliva by disrupting the disulfide linkage	physo-stigmine[92]	Cholinesterase inhibitor	1–2mg/ml Locally applied as mouthwashes or in a spray
Bentasil lozenges	Ameliorate the subjective feeling of dryness by its prolonged effect.	Other stimulants are[93, 94] Carbachol(parasympatheticomimetic) Anethole trithione(Choleretic) Bromhexine (Mucolytic agent)		

5.2.2 Acupuncture

Acupuncture is usually termed as alternative medicine[95] which utilizes numerous approaches such as infiltration by using thin needle or application of pressure (compelling force), heat or laser light to stimulate the specialized acupuncture points alongside the body skin[96]. It is an important element of traditional Chinese medicine but its clinical practice fluctuates from country to country[97].

Prior studies has been demonstrated that acupuncture is considered a comparatively prudent procedure[98] which play pivotal role in stimulating the residual secretory capacity of salivary glands in RT patients of HNC[99]. It has been proved from earlier studies that acupuncture is found to be an efficient technique in promoting the whole stimulated saliva[99, 100] and diminishing the severity of dysphagia and feeling of dryness (xerostomia)[101]. The outcome of acupuncture therapy can persist for at least 6 months which can be further prolonged up to 3 years by inclusion of other acupuncture therapy[99, 100].

5.3 Radioprotection

5.3.1 Amifostine

In order to reduce the severity of xerostomia, Amifostine (aminothiols prodrug) has been found an effective cytoprotectant, which can be used during and after radiotherapy for HNC patients [23]. It can provide direct radioprotection to parotid glands when extensive part of it involved in radiation port because it is scavenger of oxygen radical [23, 102]. It is administered by intravenous route (table 7)[103, 104]. Anné PR et al. has been demonstrated in his study that IV administration of Amifostine is associated with many side effects which can be overcome by its administration through subcutaneous route [104]. After administration, Amifostine is transformed into its active metabolite (WR-1065) by alkaline phosphatase (a membrane bound enzyme)[105]. This active metabolite is taken by

normal cells where it provides protection against harmful effects of radiation and chemotherapy. Normal cells have very high affinity (100 times than tumor cells) toward WR-1065 because of the presence of alkaline phosphatase in adequate amount. Amifostine perform its defending function by eating up free radicals, giving H^+ ion to them and have ability to inactivate the cytotoxic effects of radiation [105].

5.3.2 Tempol

It has been revealed from previous two studies of Vitolo JM et al. and Cotrim AP et al. that stable nitroxide (Tempol) is found to offer radio-protective effect by following mechanisms; imitating the action of superoxide dismutase, oxidizing transition metals and scavenging free radicals[106]. These studies were conducted in animal model (mouse) and provide evidence of the fact that radiation induced salivary gland dysfunction can be considerably reduced by administration of tempol through IV, IP, SC and in topical preparation[106, 107]. Later on, Cotrim AP and his colleague has shown in another study that tempol have tendency to provide protection only to salivary gland rather than tumor tissues[108].

5.3.3 Salivary substitutes/ artificial saliva

In order to manage the chronic xerostomia, different salivary substitutes/artificial salivas are commercially available when other stimulants (sialogogue) are failed to induce the saliva flow (residual salivary secretion)[112]. The artificial salivas are usually termed as aqueous solution preparation, chiefly comprises of glycoprotein or mucins, salivary enzymes (lysozyme, peroxidase, glucose oxidase) and polymers (carboxymethyl cellulose) that substitute the salivary gland hypofunction in severe xerostomic patients[113-115]. The artificial salivas have very close resemblance to natural human saliva in term of their chemical composition and biophysical properties (table)[116].

Table no 8: Recommended dose of Amifostine

Recommended dose of Amifostine	Frequency	Administration guidelines
200mg/m ²	Once daily	3-minute intravenous (IV) infusion, 15-30 min before starting radiotherapy.

Table no 9: protective agents

Agents	Description	References
Insulin growth factor 1 (IGF-1)	Inhibit radiation induced programmed cell death (apoptosis), and conserve salivary gland function.	[109]
keratinocyte growth factor (KGF)	Restrict the post radiation associated abnormal growth of acinar cells of salivary glands that results in improved hyposalivation effect.	[109, 110]
Botulinum toxin	Reduce radiation induced injuries to submandibular glands.	[111]

Table no 10: Natural saliva Vs artificial saliva[117]

Significant characteristics	Natural saliva	Artificial saliva
Mucoadhesive nature	✓	✓
Lubrication	✓	✓
Shielding/protection	✓	✓
Digestive action	✓	×
Enzymatic action	✓	×

6. Conclusion

In this review we have discussed about Xerostomia. That is clinically denoted by feeling of dryness in the mouth due to decreased production of saliva. Prevalence of this condition is about 20% in the general population with highest rate of incidence in females and elderly people. This review has discussed the different strategies (Stringent dental and oral hygiene, salivary glands-sparing radiation techniques, Sialogogue, acupuncture and Amifostine, tempol and Salivary substitutes) that were utilized to manage the xerostomia after radiotherapy. This study also provides sufficient information to young researcher about grading of xerostomia and several novel radio-protective agents for its management.

“Cite this Article”

A. Tariq, M. Jamshaid, I. Majeed “Xerostomia: Post Radiation Management Strategies” Int. J. of Pharm. Res. & All. Sci. 2015;4(3):35-47

References

- Guchelaar, H.-J., A. Vermes, and J. Meerwaldt, *Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment*. Supportive care in cancer, 1997. **5**(4): p. 281-288.
- Amerongen, A.N. and E. Veerman, *Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies*. Supportive care in cancer, 2003. **11**(4): p. 226-231.
- Sreebny, L.M. and A. Vissink, *Dry mouth, the malevolent symptom: a clinical guide* 2010: John Wiley & Sons.
- Navazesh, M. and I.I. Ship, *Xerostomia: diagnosis and treatment*. American journal of otolaryngology, 1983. **4**(4): p. 283-292.
- Närhi, T., *Prevalence of subjective feelings of dry mouth in the elderly*. Journal of dental research, 1994. **73**(1): p. 20-25.

6. Lenander-Lumikari, M. and V. Loimaranta, *Saliva and dental caries*. Advances in dental research, 2000. **14**(1): p. 40-47.
7. Batouli, S., et al., *Comparison of stem-cell-mediated osteogenesis and dentinogenesis*. Journal of dental research, 2003. **82**(12): p. 976-981.
8. Vollmer, W.M., et al., *Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a chlorhexidine dental coating for the prevention of adult caries*. BMC oral health, 2010. **10**(1): p. 23.
9. Jensen, S., et al., *Xerostomia and hypofunction of the salivary glands in cancer therapy*. Supportive care in cancer, 2003. **11**(4): p. 207-225.
10. Lee, Y.-H. and D.T. Wong, *Saliva: an emerging biofluid for early detection of diseases*. American journal of dentistry, 2009. **22**(4): p. 241.
11. Haas, M. and D.L. McBride, *Managing the oral effects of cancer treatment: Diagnosis to survivorship* 2011: Onc Nurs Society.
12. Jensen, S.B., et al., *A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life*. Supportive care in cancer, 2010. **18**(8): p. 1039-1060.
13. Stone, H.B., et al., *Effects of radiation on normal tissue: consequences and mechanisms*. The lancet oncology, 2003. **4**(9): p. 529-536.
14. Scully, C., *Oral and maxillofacial medicine: the basis of diagnosis and treatment* 2012: Elsevier Health Sciences.
15. Hopcraft, M. and C. Tan, *Xerostomia: an update for clinicians*. Australian dental journal, 2010. **55**(3): p. 238-244.
16. Vissink, A., et al., *Prevention and treatment of salivary gland hypofunction related to head and neck radiation therapy and chemotherapy*. Supportive cancer therapy, 2004. **1**(2): p. 111-118.
17. Langendijk, J.A., et al., *Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy*. Journal of Clinical Oncology, 2008. **26**(22): p. 3770-3776.
18. Jellema, A.P., et al., *Impact of radiation-induced xerostomia on quality of life after primary radiotherapy among patients with head and neck cancer*. International Journal of Radiation Oncology* Biology* Physics, 2007. **69**(3): p. 751-760.
19. Stevenson, H., et al., *UK patients with primary Sjögren's syndrome are at increased risk from clinical depression*. Gerodontology, 2004. **21**(3): p. 141-145.
20. Shiboski, C.H., et al., *Management of salivary hypofunction during and after radiotherapy*. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2007. **103**: p. S66. e1-S66. e19.
21. Porter, S., C. Scully, and A. Hegarty, *An update of the etiology and management of xerostomia*. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2004. **97**(1): p. 28-46.
22. Antunes, H.S., et al., *Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation*. Radiotherapy and Oncology, 2013. **109**(2): p. 297-302.
23. Brosky, M.E., *The role of saliva in oral health: strategies for prevention and management of xerostomia*. J Support Oncol, 2007. **5**(5): p. 215-225.
24. Dijkema, T., et al., *Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy*. International Journal of Radiation Oncology* Biology* Physics, 2008. **72**(4): p. 1101-1109.
25. Öhrn, K.E., Y.-B. Wahlin, and P.-O. Sjäöden, *Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of*

- oral complications*. Supportive care in cancer, 2001. **9**(4): p. 247-257.
26. Fox, P.C., et al., *Oral involvement in primary Sjögren syndrome*. The Journal of the American Dental Association, 2008. **139**(12): p. 1592-1601.
 27. Guggenheimer, J. and P.A. Moore, *Xerostomia: etiology, recognition and treatment*. The Journal of the American Dental Association, 2003. **134**(1): p. 61-69.
 28. Burket, L.W., M.S. Greenberg, and M. Glick, *Burket's oral medicine: diagnosis and treatment* 2003: PMPH-USA.
 29. O'Sullivan, E. and I. Higginson, *Clinical effectiveness and safety of acupuncture in the treatment of irradiation-induced xerostomia in patients with head and neck cancer: a systematic review*. Acupuncture in Medicine, 2010. **28**(4): p. 191-199.
 30. Eisbruch, A., et al., *Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results*. International Journal of Radiation Oncology* Biology* Physics, 1996. **36**(2): p. 469-480.
 31. Scully, C. and D. Felix, *3: Oral Medicine—Update for the dental practitioner: Dry mouth and disorders of salivation*. British dental journal, 2005. **199**(7): p. 423-427.
 32. Anurag Gupta, B., J.B. Epstein, and H. Sroussi, *Hyposalivation in elderly patients*. J Can Dent Assoc, 2006. **72**(9): p. 841-6.
 33. Rose-Ped, A.M., et al., *Complications of radiation therapy for head and neck cancers: the patient's perspective*. Cancer nursing, 2002. **25**(6): p. 461-467.
 34. Bäckström, I., et al., *Dietary intake in head and neck irradiated patients with permanent dry mouth symptoms*. European Journal of Cancer Part B: Oral Oncology, 1995. **31**(4): p. 253-257.
 35. Abramoff, M.M.F., et al., *Low-level laser therapy in the prevention and treatment of chemotherapy-induced oral mucositis in young patients*. Photomedicine and laser surgery, 2008. **26**(4): p. 393-400.
 36. Berger, A. and R. Bensadoun, [*Normal tissue tolerance to external beam radiation therapy: the mandible*]. Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique, 2010. **14**(4-5): p. 295-300.
 37. Stone, H.B., et al., *Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries report of an NCI workshop, December 3-4, 2003*. Radiation research, 2004. **162**(6): p. 711-728.
 38. Kent, M.L., et al., *Radiation-induced trismus in head and neck cancer patients*. Supportive care in cancer, 2008. **16**(3): p. 305-309.
 39. Caglar, H.B., et al., *Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy*. International Journal of Radiation Oncology* Biology* Physics, 2008. **72**(4): p. 1110-1118.
 40. Moritz, M.W., R.F. Higgins, and J.R. Jacobs, *Duplex imaging and incidence of carotid radiation injury after high-dose radiotherapy for tumors of the head and neck*. Archives of Surgery, 1990. **125**(9): p. 1181-1183.
 41. Littley, M., et al., *Hypopituitarism following external radiotherapy for pituitary tumours in adults*. QJM, 1989. **70**(2): p. 145-160.
 42. Jereczek-Fossa, B.A., et al., *Radiotherapy-induced thyroid disorders*. Cancer treatment reviews, 2004. **30**(4): p. 369-384.
 43. Schipper, J., K. Tan, and H. Van Peperzeel, *Treatment of retinoblastoma by precision megavoltage radiation therapy*. Radiotherapy and Oncology, 1985. **3**(2): p. 117-132.
 44. Parsons, J.T., et al., *Severe dry-eye syndrome following external beam irradiation*. International Journal of Radiation Oncology* Biology* Physics, 1994. **30**(4): p. 775-780.
 45. Bhandare, N., et al., *Does altered fractionation influence the risk of*

- radiation-induced optic neuropathy?* International Journal of Radiation Oncology* Biology* Physics, 2005. **62**(4): p. 1070-1077.
46. Bhandare, N., et al., *Ototoxicity after radiotherapy for head and neck tumors.* International Journal of Radiation Oncology* Biology* Physics, 2007. **67**(2): p. 469-479.
 47. Bhandare, N. and W. Mendenhall, *A literature review of late complications of radiation therapy for head and neck cancers: incidence and dose response.* J Nucl Med Radiat Ther S, 2012. **2**: p. 2.
 48. Galecki, J., et al., *Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer—a review.* Acta oncologica, 2006. **45**(3): p. 280-284.
 49. Orellana, M., et al., *Prevalence of Xerostomia in Population-based Samples: A Systematic Review.* Journal of public health dentistry, 2006. **66**(2): p. 152-158.
 50. Villa, A. and S. Abati, *Risk factors and symptoms associated with xerostomia: a cross-sectional study.* Australian dental journal, 2011. **56**(3): p. 290-295.
 51. Grisius, M.M. and P.C. Fox, *Salivary gland diseases.* Oral medicine—diagnosis and treatment. 10th edn. Spain: BC Decker Inc, 2003: p. 248.
 52. Murray, M., T. Buckenham, and A. Joseph, *The role of ultrasound in screening patients referred for sialography: a possible protocol.* Clinical Otolaryngology & Allied Sciences, 1996. **21**(1): p. 21-23.
 53. Shimizu, M., et al., *Statistical study for sonographic differential diagnosis of tumorous lesions in the parotid gland.* Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 1999. **88**(2): p. 226-233.
 54. Casselman, J.W. and A.A. Mancuso, *Major salivary gland masses: comparison of MR imaging and CT.* Radiology, 1987. **165**(1): p. 183-189.
 55. Weber, A., *Imaging of the salivary glands.* Current opinion in radiology, 1992. **4**(1): p. 117-122.
 56. Klutmann, S., et al., *Quantitative salivary gland scintigraphy.* Journal of nuclear medicine technology, 1999. **27**: p. 20-26.
 57. Ship, J., *Diagnosing, managing, and preventing salivary gland disorders.* Oral diseases, 2002. **8**(2): p. 77-89.
 58. Lomas, D.J., et al., *MR sialography. Work in progress.* Radiology, 1996. **200**(1): p. 129-133.
 59. Delbalso, A., *Salivary imaging.* Oral Maxillo-fac. Surg.—1995. Clin. North Am, 1995. **7**: p. 387-422.
 60. Mason, D., et al., *Recording the pattern of salivary flow.* Journal of dental research, 1966. **45**(5): p. 1458-1463.
 61. Adams, B., H. Al Attia, and S. Parkar, *Salivary gland scintigraphy in Sjögren's syndrome: are quantitative indices the answer?* Nuclear medicine communications, 2003. **24**(9): p. 1011-1016.
 62. Trotti, A., et al., *Patient-reported outcomes and the evolution of adverse event reporting in oncology.* Journal of Clinical Oncology, 2007. **25**(32): p. 5121-5127.
 63. Eisbruch, A., et al., *Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.* International Journal of Radiation Oncology* Biology* Physics, 2001. **50**(3): p. 695-704.
 64. Fox, P.C., K. Busch, and B. Baum, *Subjective reports of xerostomia and objective measures of salivary gland performance.* Journal of the American Dental Association (1939), 1987. **115**(4): p. 581-584.
 65. Meirovitz, A., et al., *Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.* International Journal of Radiation Oncology* Biology* Physics, 2006. **66**(2): p. 445-453.

66. Denis, F., et al., *Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.* International Journal of Radiation Oncology* Biology* Physics, 2003. **55**(1): p. 93-98.
67. Berk, L.B., A.T. Shivnani, and W. Small Jr, *Pathophysiology and management of radiation-induced xerostomia.* J Support Oncol, 2005. **3**(3): p. 191-200.
68. Brizel, D.M., et al., *Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.* Journal of Clinical Oncology, 2000. **18**(19): p. 3339-3345.
69. Taweechaisupapong, S., et al., *Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer.* Australian dental journal, 2006. **51**(4): p. 333-337.
70. Patton, L.L., B.A. White, and M.J. Field, *State of the evidence base for medically necessary oral health care.* Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2001. **92**(3): p. 272-275.
71. Research, N.I.o.D., et al., *Oral complications of cancer therapies: diagnosis, prevention, and treatment.* Vol. 7. 1989: US Department of Health and Human Services, Public Health Service, National Institutes of Health, Office of Medical Applications of Research.
72. Mackie, A., et al., *Nasopharyngeal carcinoma: the role of the dentist in assessment, early diagnosis and care before and after cancer therapy.* Oral oncology, 2000. **36**(5): p. 397-403.
73. Cassolato, S.F. and R.S. Turnbull, *Xerostomia: clinical aspects and treatment.* Gerodontology, 2003. **20**(2): p. 64-77.
74. Saarilahti, K., et al., *Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer.* Radiotherapy and Oncology, 2006. **78**(3): p. 270-275.
75. Li, Y., et al., *The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy.* International Journal of Radiation Oncology* Biology* Physics, 2007. **67**(3): p. 660-669.
76. Deasy, J.O., et al., *Radiotherapy dose-volume effects on salivary gland function.* International Journal of Radiation Oncology* Biology* Physics, 2010. **76**(3): p. S58-S63.
77. Eisbruch, A., et al., *Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.* International Journal of Radiation Oncology* Biology* Physics, 1999. **45**(3): p. 577-587.
78. Teymoortash, A., et al., *Botulinum toxin prevents radiotherapy-induced salivary gland damage.* Oral oncology, 2009. **45**(8): p. 737-739.
79. Jensen, S.B., et al., *A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.* Supportive care in cancer, 2010. **18**(8): p. 1061-1079.
80. Christianen, M.E., et al., *Predictive modelling for swallowing dysfunction after primary (chemo) radiation: results of a prospective observational study.* Radiotherapy and Oncology, 2012. **105**(1): p. 107-114.
81. Steneker, M., A. Lomax, and U. Schneider, *Intensity modulated photon and proton therapy for the treatment of head and neck tumors.* Radiotherapy and Oncology, 2006. **80**(2): p. 263-267.
82. Wada, A., et al., *Radiation-induced xerostomia: objective evaluation of salivary gland injury using MR sialography.* American Journal of Neuroradiology, 2009. **30**(1): p. 53-58.
83. Visvanathan, V. and P. Nix, *Managing the patient presenting with xerostomia: a*

- review. International journal of clinical practice, 2010. **64**(3): p. 404-407.
84. Papas, A., et al., *Stimulation of salivary flow with a powered toothbrush in a xerostomic population*. Special Care in Dentistry, 2006. **26**(6): p. 241-246.
 85. Vivino, F.B., *The treatment of Sjögren's syndrome patients with pilocarpine-tablets*. Scandinavian Journal of Rheumatology, 2001. **30**(115): p. 1-13.
 86. da Silva Marques, D.N., et al., *Effects of gustatory stimulants of salivary secretion on salivary pH and flow in patients with Sjögren's syndrome: a randomized controlled trial*. Journal of Oral Pathology & Medicine, 2011. **40**(10): p. 785-792.
 87. Ramos-Casals, M., et al., *Treatment of primary Sjögren syndrome: a systematic review*. Jama, 2010. **304**(4): p. 452-460.
 88. Grisius, M.M., *Salivary gland dysfunction: a review of systemic therapies*. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology, 2001. **92**(2): p. 156-162.
 89. Epstein, J., W. Decoteau, and A. Wilkinson, *Effect of Sialor in treatment of xerostomia in Sjögren's syndrome*. Oral surgery, oral medicine, oral pathology, 1983. **56**(5): p. 495-499.
 90. Kao, H.J., et al., *Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles*. Journal of pharmacy and pharmacology, 2006. **58**(2): p. 179-186.
 91. Schenkels, L.C., E.C. Veerman, and A.V.N. Amerongen, *Biochemical composition of human saliva in relation to other mucosal fluids*. Critical reviews in oral biology & medicine, 1995. **6**(2): p. 161-175.
 92. Ekström, J. and H.F. Helander, *Secretion from submucosal salivary glands of the ferret in response to a cholinesterase inhibitor applied onto the oral mucosa*. European journal of oral sciences, 2002. **110**(3): p. 230-236.
 93. Hedner, E., et al., *Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitor physostigmine in man*. European journal of oral sciences, 2001. **109**(6): p. 371-374.
 94. Nagano, T. and M. Takeyama, *Enhancement of salivary secretion and neuropeptide (substance P, α -calcitonin gene-related peptide) levels in saliva by chronic anethole trithione treatment*. Journal of pharmacy and pharmacology, 2001. **53**(12): p. 1697-1702.
 95. Mohan, M., et al., *Pharmacological agents in dentistry: a review*. Br J Pharm Res, 2011. **1**(3): p. 66-87.
 96. Berman, B.M., et al., *Acupuncture for chronic low back pain*. New England Journal of Medicine, 2010. **363**(5): p. 454-461.
 97. Adams, D., et al., *The safety of pediatric acupuncture: a systematic review*. Pediatrics, 2011: p. peds. 2011-1091.
 98. Liu, G., et al., *Effects of painful stimulation and acupuncture on attention networks in healthy subjects*. Behavioral and Brain Functions, 2013. **9**(1): p. 23.
 99. Manheimer, E., et al., *Acupuncture for treatment of irritable bowel syndrome*. The Cochrane Library, 2012.
 100. Vissink, A., et al., *Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers*. International Journal of Radiation Oncology* Biology* Physics, 2010. **78**(4): p. 983-991.
 101. Braga, F.d.P.F., et al., *Acupuncture for the prevention of radiation-induced xerostomia in patients with head and neck cancer*. Brazilian oral research, 2011. **25**(2): p. 180-185.
 102. Schuchter, L.M., et al., *2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology*. Journal of Clinical Oncology, 2002. **20**(12): p. 2895-2903.
 103. Furness, S., et al., *Interventions for the management of dry mouth:*

- non-pharmacological interventions*. The Cochrane Library, 2013.
104. Culy, C.R. and C.M. Spencer, *Amifostine*. Drugs, 2001. **61**(5): p. 641-684.
105. Hensley, M.L., et al., *American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants*. Journal of Clinical Oncology, 2009. **27**(1): p. 127-145.
106. Anné, P.R., et al., *A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer*. International Journal of Radiation Oncology* Biology* Physics, 2007. **67**(2): p. 445-452.
107. Vitolo, J.M., et al., *The stable nitroxide tempol facilitates salivary gland protection during head and neck irradiation in a mouse model*. Clinical Cancer Research, 2004. **10**(5): p. 1807-1812.
108. Cotrim, A.P., et al., *Kinetics of tempol for prevention of xerostomia following head and neck irradiation in a mouse model*. Clinical Cancer Research, 2005. **11**(20): p. 7564-7568.
109. Cotrim, A.P., et al., *Differential radiation protection of salivary glands versus tumor by Tempol with accompanying tissue assessment of Tempol by magnetic resonance imaging*. Clinical Cancer Research, 2007. **13**(16): p. 4928-4933.
110. Avila, J.L., et al., *Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis*. International Journal of Radiation Oncology* Biology* Physics, 2009. **73**(2): p. 523-529.
111. Lombaert, I., et al., *Keratinocyte growth factor prevents radiation damage to salivary glands by expansion of the stem/progenitor pool*. Stem Cells, 2008. **26**(10): p. 2595-2601.
112. Levine, M., et al., *Artificial salivas: present and future*. Journal of dental research, 1987. **66**(2 suppl): p. 693-698.
113. Vissink, A., et al., *Rheological properties of saliva substitutes containing mucin, carboxymethylcellulose or polyethylenoxide*. Journal of Oral Pathology & Medicine, 1984. **13**(1): p. 22-28.
114. Chauncey, H.H., *Salivary enzymes*. The Journal of the American Dental Association, 1961. **63**(3): p. 360-368.
115. Davies, A. and J. Singer, *A comparison of artificial saliva and pilocarpine in radiation induced xerostomia*. The Journal of Laryngology & Otology, 1994. **108**(08): p. 663-665.
116. Schipper, R.G., E. Silletti, and M.H. Vingerhoeds, *Saliva as research material: biochemical, physicochemical and practical aspects*. Archives of oral biology, 2007. **52**(12): p. 1114-1135.
117. Preetha, A. and R. Banerjee, *Comparison of artificial saliva substitutes*. Trends Biomater Artif Organs, 2005. **18**(2): p. 178-186.
-